Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
Last trade$270.38
Day change-$1.35 (-0.50%)
Day range$260.94 – $281.35
Volume356,617
Market cap$17.82B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for ASND.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ASND, quarterly periods
Line item
Q2 FY2019 Jun 30, 2019
Q1 FY2019 Mar 31, 2019
Q4 FY2018 Dec 31, 2018
Q3 FY2018 Sep 30, 2018
Q2 FY2018 Jun 30, 2018
Q1 FY2018 Mar 31, 2018
Q4 FY2017 Dec 31, 2017
Q3 FY2017 Sep 30, 2017
Revenue
$157K
—
$1.48M
$40.79M
$9.04M
$8.2M
$4.27M
$27.19M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$157K
—
$1.48M
$40.79M
$9.04M
$8.2M
$4.27M
$27.19M
Selling, general and administrative
$10.15M
$11.77M
$10.82M
$10.29M
$11.29M
$11.2M
$8.82M
$8.11M
Research and development
$25.51M
$22.02M
$22.77M
$23.48M
$26.62M
$25.73M
$25.15M
$24.03M
Total operating expenses
$35.66M
$33.79M
$33.59M
$33.77M
$37.92M
$36.94M
$33.97M
$32.15M
Operating income
-$35.5M
-$33.79M
-$32.11M
$7.02M
-$28.88M
-$28.74M
-$29.7M
-$4.96M
Interest expense
—
—
—
—
—
—
—
—
Income before taxes
-$41.02M
-$27.41M
-$36.04M
$5.38M
-$43.74M
-$20.95M
-$27.43M
-$653K
Income taxes
$65K
$2K
$135K
$133K
$102K
$127K
-$170K
$225K
Net income
-$41.09M
-$27.41M
-$36.17M
$5.24M
-$43.85M
-$21.08M
-$27.26M
-$878K
Net income attributable to common shareholders
-$41.09M
-$27.41M
-$36.17M
$5.24M
-$43.85M
-$21.08M
-$27.26M
-$878K
EBITDA
-$33.52M
-$31.8M
-$32.11M
$8.93M
-$26.96M
-$26.86M
-$27.96M
-$3.46M
Basic earnings per share
-$0.07
-$0.04
-$0.06
$0.01
-$0.08
-$0.04
-$0.05
—
Diluted earnings per share
-$0.07
-$0.04
-$0.06
$0.01
-$0.08
-$0.04
-$0.05
—
Recent news
Company coverage with links to the original publishers.
The global peptide therapeutics market is projected to grow from $112.20 billion in 2026 to $229.32 billion by 2036 at a 7.4% CAGR, driven by GLP-1 and incretin therapies, oral peptides, radioligands, and generic competition. Eli Lilly and Novo Nordisk lead the market with blockbuster incretin products, while emerging opportunities include oral macrocyclic peptides, radioligands, and generic semaglutide following patent expiry in major markets.
REX Shares launched the REX Peptide ETF (PEPT), offering global exposure to peptide drug developers, manufacturers, and delivery platforms. The fund tracks the VettaFi Peptide Index and charges 65 bps in fees. With GLP-1 adoption expanding and the global incretin market projected to reach $200 billion by 2030, the peptide market is positioned for significant growth. PEPT competes with similar ETFs THNR and OZEM, which charge 59 bps each.
Ascendis Pharma announced that the European Medicines Agency's CHMP committee issued a positive opinion for TransCon CNP (Navepegritide), a once-weekly treatment for achondroplasia in children aged 2+ years with open epiphyses. The European Commission is expected to make a final decision in Q4 2026, with market launch in Germany anticipated for Q1 2027 under the brand name YUVIWEL®. The drug was previously approved by the FDA in February 2026.
Ascendis Pharma announced that the European Medicines Agency's CHMP committee issued a positive opinion recommending approval of TransCon CNP (navepegritide) for treating achondroplasia in children aged 2+ with open epiphyses. The European Commission's final decision is expected in Q4 2026, with commercial launch planned in Germany in Q1 2027 under the brand name YUVIWEL®.
BridgeBio Pharma announced FDA acceptance of its regulatory filing for infigratinib, an oral drug to treat achondroplasia in children, with priority review and a decision expected by February 4, 2027. The drug demonstrated 2.1 cm/year greater height growth than placebo in Phase III trials. If approved, it would be the first oral therapy for achondroplasia, differentiating it from injectable competitors. BridgeBio also has two other near-term regulatory catalysts (BBP-418 and encaleret) that could diversify its revenue beyond its current marketed product Attruby.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.